208 related articles for article (PubMed ID: 23887741)
1. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.
García-González MJ; de Mora-Martín M; López-Fernández S; López-Díaz J; Martínez-Sellés M; Romero-García J; Cordero M; Lara-Padrón A; Marrero-Rodríguez F; del Mar García-Saiz M; Aldea-Perona A;
Cardiovasc Drugs Ther; 2013 Dec; 27(6):573-9. PubMed ID: 23887741
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.
García-González MJ; Aldea Perona A; Lara Padron A; Morales Rull JL; Martínez-Sellés M; de Mora Martin M; López Díaz J; López Fernandez S; Ortiz Oficialdegui P; Jiménez Sosa A
ESC Heart Fail; 2021 Dec; 8(6):4820-4831. PubMed ID: 34716753
[TBL] [Abstract][Full Text] [Related]
3. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
7. An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.
Orme RM; Perkins GD; McAuley DF; Liu KD; Mason AJ; Morelli A; Singer M; Ashby D; Gordon AC
Trials; 2014 Jun; 15():199. PubMed ID: 24894386
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction.
Jia Z; Guo M; Zhang YQ; Liang HQ; Zhang LY; Song Y
Cardiology; 2014; 128(2):195-201. PubMed ID: 24751462
[TBL] [Abstract][Full Text] [Related]
10. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.
Pölzl G; Allipour Birgani S; Comín-Colet J; Delgado JF; Fedele F; García-Gonzáles MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Vrtovec B; Wikström G; Altenberger J
ESC Heart Fail; 2019 Feb; 6(1):174-181. PubMed ID: 30378288
[TBL] [Abstract][Full Text] [Related]
11. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design.
Tycińska A; Gierlotka M; Bartuś S; Gąsior M; Główczyńska R; Grześk G; Jaguszewski M; Kasprzak JD; Kubica J; Legutko J; Leszek P; Nessler J; Pacileo G; Ponikowski P; Sobkowicz B; Stępińska J; Straburzyńska-Migaj E; Wojakowski W; Zawiślak B; Zymliński R;
Adv Med Sci; 2022 Mar; 67(1):18-22. PubMed ID: 34656873
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
Husebye T; Eritsland J; Müller C; Sandvik L; Arnesen H; Seljeflot I; Mangschau A; Bjørnerheim R; Andersen GØ
Eur J Heart Fail; 2013 May; 15(5):565-72. PubMed ID: 23288914
[TBL] [Abstract][Full Text] [Related]
14. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
Silvetti S; Nieminen MS
Int J Cardiol; 2016 Jan; 202():138-43. PubMed ID: 26386941
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
Manito Lorite N; Rubio-Rodríguez D; González Costello J; Díez López C; Enjuanes Grau C; Segovia-Cubero J; Delgado Jimenez JF; Campo Sien C; Rubio-Terrés C; Comín-Colet J; ;
Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):361-367. PubMed ID: 31899185
[TBL] [Abstract][Full Text] [Related]
16. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial.
Pölzl G; Altenberger J; Comín-Colet J; Delgado JF; Fedele F; García-González MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Maier S; Vrtovec B; Wikström G; Zima E; Bauer A;
Eur J Heart Fail; 2023 Nov; 25(11):2007-2017. PubMed ID: 37634941
[TBL] [Abstract][Full Text] [Related]
17. ST-segment elevation during levosimendan infusion.
Barillà F; Giordano F; Jacomelli I; Pellicano M; Dominici T
J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):454-6. PubMed ID: 22673026
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial.
Lahtinen P; Pitkänen O; Pölönen P; Turpeinen A; Kiviniemi V; Uusaro A
Crit Care Med; 2011 Oct; 39(10):2263-70. PubMed ID: 21666445
[TBL] [Abstract][Full Text] [Related]
19. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan for Hemodynamic Support after Cardiac Surgery.
Landoni G; Lomivorotov VV; Alvaro G; Lobreglio R; Pisano A; Guarracino F; Calabrò MG; Grigoryev EV; Likhvantsev VV; Salgado-Filho MF; Bianchi A; Pasyuga VV; Baiocchi M; Pappalardo F; Monaco F; Boboshko VA; Abubakirov MN; Amantea B; Lembo R; Brazzi L; Verniero L; Bertini P; Scandroglio AM; Bove T; Belletti A; Michienzi MG; Shukevich DL; Zabelina TS; Bellomo R; Zangrillo A;
N Engl J Med; 2017 May; 376(21):2021-2031. PubMed ID: 28320259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
